It is very uncertain whether hypoxia‐inducible factor (HIF) stabilisers changes cardiovascular death Median compared with placebo (very low certainty).
The review found no eligible studies for this question.
Hypoxia‐inducible factor (HIF) stabilisers showed no clear difference in nonfatal myocardial infarction Median compared with erythropoiesis‐stimulating agent (ESA) (low certainty).
Hypoxia‐inducible factor (HIF) stabilisers showed no clear difference in nonfatal stroke Median compared with erythropoiesis‐stimulating agent (ESA) (low certainty).
Hypoxia‐inducible factor (HIF) stabilisers showed no clear difference in proportion of patients requiring blood transfusion Median compared with erythropoiesis‐stimulating agent (ESA) (moderate certainty).
Hypoxia‐inducible factor (HIF) stabilisers showed no clear difference in proportion reaching target haemoglobin Median compared with erythropoiesis‐stimulating agent (ESA) (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether hypoxia‐inducible factor (HIF) stabilisers changes nonfatal myocardial infarction Median compared with placebo (very low certainty).
Hypoxia‐inducible factor (HIF) stabilisers probably leads to lower proportion of patients requiring blood transfusion Median compared with placebo (moderate certainty).
Hypoxia‐inducible factor (HIF) stabilisers probably leads to higher proportion reaching target haemoglobin Median compared with placebo (moderate certainty).
Hypoxia‐inducible factor (HIF) stabilisers showed no clear difference in cardiovascular death Median compared with erythropoiesis‐stimulating agent (ESA) (low certainty).
It is very uncertain whether hypoxia‐inducible factor (HIF) stabilisers changes fatigue Median compared with erythropoiesis‐stimulating agent (ESA) (very low certainty).